Pure Global

Study to Evaluate the Possible Antifibrotic Effect of Zinc Sulphate in Chronic HCV Patient Receiving Direct Acting Anti-viral Therapy. - Trial NCT05465434

Access comprehensive clinical trial information for NCT05465434 through Pure Global AI's free database. This Phase 3 trial is sponsored by Tanta University and is currently Not yet recruiting. The study focuses on Hepatitis C. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05465434
Phase 3
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov โ€ข NCT05465434
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Study to Evaluate the Possible Antifibrotic Effect of Zinc Sulphate in Chronic HCV Patient Receiving Direct Acting Anti-viral Therapy.
Study to Evaluate the Possible Antifibrotic Effect of Zinc Sulphate in Chronic HCV Patient Receiving Direct Acting Anti-viral Therapy

Study Focus

Hepatitis C

Zinc Supplement

Interventional

drug

Sponsor & Location

Tanta University

Timeline & Enrollment

Phase 3

Aug 01, 2022

Nov 30, 2023

50 participants

Primary Outcome

Abdominal Ultrasonography,Serum fibronectin level,Serum transforming growth factor - beta 1 (TGF- ฮฒ1) level,Fibrosis-4 (FIB-4) Score,AST to Platelet Ratio Index (APRI) score,Serum hyaluronic acid level

Summary

This study aims to evaluate the possible antifibrotic effect of zinc sulphate in chronic HCV
 patient receiving direct acting anti-viral therapy

ICD-10 Classifications

Acute hepatitis C
Chronic viral hepatitis C
Viral hepatitis
Chronic viral hepatitis
Unspecified viral hepatitis

Data Source

ClinicalTrials.gov

NCT05465434

Non-Device Trial